LY 451395

Known as: LY-451395, LY451395 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2018
02420062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor (AMPA-R) potentiators with brain-derived neurotrophic… (More)
Is this relevant?
2013
2013
N-Methyl-d-aspartate receptor (NMDAR) antagonists mimic several symptoms of schizophrenia in healthy subjects, and are used in… (More)
Is this relevant?
2013
2013
BACKGROUND Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Dysfunction of the prefrontal cortex (PFC) is considered to be an important factor contributing to a decrease in cognitive… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2008
2008
We present a substantial series of behavioral and imaging experiments, which demonstrate, for the first time, that increasing… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2007
2007
OBJECTIVE To investigate the efficacy and safety of the positive alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid… (More)
Is this relevant?
2006
2006
The objective of this study was to measure the steady-state cerebrospinal fluid (CSF) concentration of LY450108 and LY451395… (More)
Is this relevant?
2006
2006
LY451395 (2-propanesulfonamide, N-[(2R)-2-[4'-[2-[methylsulfonyl)amino]ethyl][1,1'-biphenyl]-4-yl]propyl]-) is a potent and… (More)
Is this relevant?